Abstract
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study
Neurotherapeutics, Vol.7(3), pp.329-330
07/2010
DOI: 10.1016/j.nurt.2010.06.008
Abstract
We previously described a composite cerebral MRI scale combining T1 lesions, T2 lesions, and whole brain atrophy in multiple sclerosis (MS) patients: the Magnetic Resonance Disease Severity Scale (MRDSS).
Test the strength of the MRDSS vs. individual MRI measures for sensitivity to longitudinal change.
We prospectively studied 84 patients [age (mean ± SD) 42.6 ± 8.6 years, EDSS score 3.2 ± 2.1, 68% (
n = 57) relapsing–remitting (RR), 24% (
n = 20) secondary progressive (SP), and 8.3% (
n = 7) primary progressive] over a follow-up period of 3.2 ± 0.3 years. Baseline and follow-up brain MRI derived T2 lesion volume (T2LV), T1 hypointense lesion volume (T1LV), and brain parenchymal fraction (BPF). The ratio of T1LV to T2LV assessed lesion severity. MRDSS for each patient was the combination of T2LV, BPF, and T1/T2 ratio. Wilcoxon signed rank test assessed change in each measure over follow-up.
Patients had higher (worse) MRDSS at follow-up (5.5 ± 2.3) vs. baseline (4.9 ± 2.4;
p < 0.001). Regarding the individual standardized and unstandardized components of MRDSS, BPF decreased (
p < 0.001), T1/T2 increased (
p < 0.001), but T2LV was unchanged (
p > 0.5). Change in MRDSS was larger than change in individual MRI components. Although MRDSS showed a significant change in both RR (entry 4.4 ± 2.4 vs. exit 5.2 ± 2.3;
p < 0.001) and SP (entry 6.4 ± 1.8 vs. exit 6.7 ± 1.9;
p < 0.05) groups, standardized and unstandardized BPF and T1/T2 ratio changed only in the RR (
p < 0.001) but not in the SP group (
p > 0.05). Longitudinal change in MRDSS was significantly different between RR and SP groups (
p = 0.002); however, the change in the individual standardized and unstandardized MRI components did not differ between groups (
p > 0.1).
These results suggest the improved sensitivity to longitudinal change of MRDSS vs. individual MRI measures of lesions and atrophy in both RR and SP MS. Although MRDSS shows sensitivity in the progressive phase, it has particular sensitivity in the RR stage of disease. MRDSS shows potential as a tool to monitor disease evolution in MS.
This study was supported by grants from the
National Institutes of Health (
R01NS055083-01) and the
National Multiple Sclerosis Society (
RG3705A1 and
RG3798A2).
Details
- Title: Subtitle
- Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study
- Creators
- Shahamat S. Tauhid - National MS Center MelsbroekJenniffer Moodie - University of Massachusetts Chan Medical SchoolMohit Neema - National MS Center MelsbroekBrian C. Healy - Brigham and Women's HospitalGuy J. Buckle - Brigham and Women's HospitalSusan A. Gauthier - Harvard UniversityBonnie I. Glanz - Brigham and Women's HospitalTanuja Chitnis - Brigham and Women's HospitalSamia J. Khoury - Brigham and Women's HospitalCharles R.G. Guttmann - Brigham and Women's HospitalHoward L. Weiner - Brigham and Women's HospitalRohit Bakshi - Brigham and Women's Hospital
- Resource Type
- Abstract
- Publication Details
- Neurotherapeutics, Vol.7(3), pp.329-330
- DOI
- 10.1016/j.nurt.2010.06.008
- ISSN
- 1933-7213
- eISSN
- 1878-7479
- Publisher
- Elsevier Inc
- Grant note
- R01NS055083-01 / National Institutes of Health RG3705A1; RG3798A2 / National Multiple Sclerosis Society
- Language
- English
- Date published
- 07/2010
- Academic Unit
- Psychiatry
- Record Identifier
- 9984631940902771
Metrics
13 Record Views